Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Completed · Phase 2

Conditions studied: Glomerulosclerosis, Focal Segmental

In brief

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

Key facts

Study ID
NCT04340362
Run by
Vertex Pharmaceuticals Incorporated
People needed
16
Starts
2020-06-08
Expected to finish
2021-12-09
Last updated by the study team
2025-09-24

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.